Twist Bioscience Corp vs Yum! Brands, Inc. — how do they compare? Twist Bioscience Corp trades at $159.78 (market cap $10.08B), while Yum! Brands, Inc. trades at $144.82 (market cap $39.02B). The key difference: Yum! Brands, Inc. is far larger — about 3.9× Twist Bioscience Corp's market cap, and Yum! Brands, Inc. pays a 2.1% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Yum! Brands, Inc. for 132 Days on average.
| TWST | YUM | |
|---|---|---|
Market Cap | $10.08B | $39.02B |
Volume | 4,229,037 | 2,597,636 |
Sector | Health | Consumer Cyclical |
52-Week High | $205.00 | $168.16 |
52-Week Low | $25.45 | $135.77 |
Typical Hold Time | 27 Days | 132 Days |
Enterprise Value | $10.01B | $50.63B |
Dividend Yield | — | 2.1% |
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $159.78, up 2.65% today, showing strong momentum despite mixed technical signals. The company continues to demonstrate robust revenue growth, with 2025 revenue reaching $377 million, though profitability remains elusive with a -31.66% net income margin. Recent positive developments include a strategic partnership with Eli Lilly's TuneLab AI platform announced September 16, 2026, driving investor optimism about the company's AI-driven drug discovery capabilities.
While analyst consensus remains bullish with 73% buy ratings, the stock faces significant fundamental challenges including persistent cash burn and negative earnings. The current price exceeds the $145.20 consensus target, suggesting limited near-term upside. Key risks include execution challenges in achieving profitability and dependence on AI partnerships for growth catalysts.
YUM trades at $143.00, up 1.89% over 24 hours, with a bullish technical signal and strong support at $141. Revenue has grown from $6.8B in 2022 to $8.2B in 2025, with net income reaching $1.56B. Recent news highlights KFC's new Open House restaurant concept in Texas, testing expanded menus and customer experiences.
The outlook remains positive with a consensus price target of $170.44, though risks include high debt levels and competitive pressures. Earnings have beaten expectations in two of the last three quarters, with Q3 2026 results pending. Analyst sentiment is mixed with 39.22% buy ratings, 54.9% hold, and 5.88% sell.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →